CMMB vs. GANX, NBRV, EGRX, AADI, OCUP, EYEN, NXTC, CLNN, DARE, and HCWB
Should you be buying Chemomab Therapeutics stock or one of its competitors? The main competitors of Chemomab Therapeutics include Gain Therapeutics (GANX), Nabriva Therapeutics (NBRV), Eagle Pharmaceuticals (EGRX), Aadi Bioscience (AADI), Ocuphire Pharma (OCUP), Eyenovia (EYEN), NextCure (NXTC), Clene (CLNN), Daré Bioscience (DARE), and HCW Biologics (HCWB). These companies are all part of the "pharmaceutical preparations" industry.
Chemomab Therapeutics (NASDAQ:CMMB) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, community ranking, earnings, profitability and media sentiment.
Chemomab Therapeutics has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500. Comparatively, Gain Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500.
46.1% of Chemomab Therapeutics shares are held by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are held by institutional investors. 11.9% of Chemomab Therapeutics shares are held by insiders. Comparatively, 11.7% of Gain Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Chemomab Therapeutics presently has a consensus price target of $5.67, indicating a potential upside of 429.64%. Gain Therapeutics has a consensus price target of $8.50, indicating a potential upside of 233.33%. Given Chemomab Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Chemomab Therapeutics is more favorable than Gain Therapeutics.
Chemomab Therapeutics' return on equity of -109.92% beat Gain Therapeutics' return on equity.
In the previous week, Gain Therapeutics had 7 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 9 mentions for Gain Therapeutics and 2 mentions for Chemomab Therapeutics. Chemomab Therapeutics' average media sentiment score of 1.44 beat Gain Therapeutics' score of 1.34 indicating that Chemomab Therapeutics is being referred to more favorably in the media.
Gain Therapeutics has higher revenue and earnings than Chemomab Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks.
Gain Therapeutics received 7 more outperform votes than Chemomab Therapeutics when rated by MarketBeat users. Likewise, 63.16% of users gave Gain Therapeutics an outperform vote while only 62.96% of users gave Chemomab Therapeutics an outperform vote.
Summary
Chemomab Therapeutics beats Gain Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Chemomab Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMMB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CMMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Chemomab Therapeutics Competitors List
Related Companies and Tools
